Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Wave Life Sciences (WVE) over the last 11 years, with Q3 2025 value amounting to -$44.9 million.

  • Wave Life Sciences' Free Cash Flow rose 415.48% to -$44.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$198.2 million, marking a year-over-year decrease of 3972.85%. This contributed to the annual value of -$152.0 million for FY2024, which is 63962.82% down from last year.
  • Wave Life Sciences' Free Cash Flow amounted to -$44.9 million in Q3 2025, which was up 415.48% from -$46.3 million recorded in Q2 2025.
  • In the past 5 years, Wave Life Sciences' Free Cash Flow registered a high of $85.0 million during Q1 2023, and its lowest value of -$63.2 million during Q1 2025.
  • Over the past 5 years, Wave Life Sciences' median Free Cash Flow value was -$33.8 million (recorded in 2024), while the average stood at -$28.7 million.
  • As far as peak fluctuations go, Wave Life Sciences' Free Cash Flow crashed by 37735.53% in 2022, and later skyrocketed by 31215.29% in 2023.
  • Wave Life Sciences' Free Cash Flow (Quarter) stood at -$7.0 million in 2021, then crashed by 377.36% to -$33.6 million in 2022, then increased by 0.15% to -$33.6 million in 2023, then tumbled by 30.18% to -$43.7 million in 2024, then fell by 2.7% to -$44.9 million in 2025.
  • Its last three reported values are -$44.9 million in Q3 2025, -$46.3 million for Q2 2025, and -$63.2 million during Q1 2025.